114 related articles for article (PubMed ID: 8683875)
1. [Cancer detection with whole-body FDG PET images without attenuation correction].
Yasuda S; Ide M; Takagi S; Shohtsu A; Mitomi T; Kobayashi S; Suzuki Y
Kaku Igaku; 1996 Apr; 33(4):367-73. PubMed ID: 8683875
[TBL] [Abstract][Full Text] [Related]
2. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images.
Imran MB; Kubota K; Yamada S; Fukuda H; Yamada K; Fujiwara T; Itoh M
J Nucl Med; 1998 Jul; 39(7):1219-23. PubMed ID: 9669398
[TBL] [Abstract][Full Text] [Related]
3. Whole-body positron emission tomography in clinical oncology: comparison between attenuation-corrected and uncorrected images.
Bengel FM; Ziegler SI; Avril N; Weber W; Laubenbacher C; Schwaiger M
Eur J Nucl Med; 1997 Sep; 24(9):1091-8. PubMed ID: 9283100
[TBL] [Abstract][Full Text] [Related]
4. Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction.
Lonneux M; Borbath I; Bol A; Coppens A; Sibomana M; Bausart R; Defrise M; Pauwels S; Michel C
Eur J Nucl Med; 1999 Jun; 26(6):591-8. PubMed ID: 10369944
[TBL] [Abstract][Full Text] [Related]
5. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose.
Hoh CK; Hawkins RA; Glaspy JA; Dahlbom M; Tse NY; Hoffman EJ; Schiepers C; Choi Y; Rege S; Nitzsche E
J Comput Assist Tomogr; 1993; 17(4):582-9. PubMed ID: 8331230
[TBL] [Abstract][Full Text] [Related]
6. [Cancer screening with whole-body FDG PET].
Yasuda S; Ide M; Takagi S; Shohtsu A
Kaku Igaku; 1996 Oct; 33(10):1065-71. PubMed ID: 8952258
[TBL] [Abstract][Full Text] [Related]
7. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection.
Zimny M; Kaiser HJ; Cremerius U; Reinartz P; Schreckenberger M; Sabri O; Buell U
Eur J Nucl Med; 1999 Aug; 26(8):818-23. PubMed ID: 10436193
[TBL] [Abstract][Full Text] [Related]
8. Untreated lung cancer: quantification of systematic distortion of tumor size and shape on non-attenuation-corrected 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET scans.
Zasadny KR; Kison PV; Quint LE; Wahl RL
Radiology; 1996 Dec; 201(3):873-6. PubMed ID: 8939245
[TBL] [Abstract][Full Text] [Related]
9. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
Delbeke D; Martin WH; Patton JA; Sandler MP
Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
[TBL] [Abstract][Full Text] [Related]
10. Whole-body positron emission tomography: Part I. Methods and performance characteristics.
Dahlbom M; Hoffman EJ; Hoh CK; Schiepers C; Rosenqvist G; Hawkins RA; Phelps ME
J Nucl Med; 1992 Jun; 33(6):1191-9. PubMed ID: 1597738
[TBL] [Abstract][Full Text] [Related]
11. Detection of malignancies with SPECT versus PET, with 2-[fluorine-18]fluoro-2-deoxy-D-glucose.
Martin WH; Delbeke D; Patton JA; Sandler MP
Radiology; 1996 Jan; 198(1):225-31. PubMed ID: 8539384
[TBL] [Abstract][Full Text] [Related]
12. Optimal dose of 18F-FDG required for whole-body PET using an LSO PET camera.
Everaert H; Vanhove C; Lahoutte T; Muylle K; Caveliers V; Bossuyt A; Franken PR
Eur J Nucl Med Mol Imaging; 2003 Dec; 30(12):1615-9. PubMed ID: 14504831
[TBL] [Abstract][Full Text] [Related]
13. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer.
Bleckmann C; Dose J; Bohuslavizki KH; Buchert R; Klutmann S; Mester J; Jänicke F; Clausen M
J Nucl Med; 1999 Dec; 40(12):2021-4. PubMed ID: 10616880
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of a short acquisition protocol for whole-body positron emission tomography with fluorine-18 fluorodeoxyglucose.
Paul AK; Tatsumi M; Fujino K; Hashikawa K; Nishimura T
Eur J Nucl Med; 2001 Nov; 28(11):1697-701. PubMed ID: 11702113
[TBL] [Abstract][Full Text] [Related]
15. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
Inoue T; Kim EE; Wong FC; Yang DJ; Bassa P; Wong WH; Korkmaz M; Tansey W; Hicks K; Podoloff DA
J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
[TBL] [Abstract][Full Text] [Related]
16. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images.
Nakamoto Y; Osman M; Cohade C; Marshall LT; Links JM; Kohlmyer S; Wahl RL
J Nucl Med; 2002 Sep; 43(9):1137-43. PubMed ID: 12215550
[TBL] [Abstract][Full Text] [Related]
17. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
[TBL] [Abstract][Full Text] [Related]
18. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
[TBL] [Abstract][Full Text] [Related]
19. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
20. Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma.
Karlan BY; Hawkins R; Hoh C; Lee M; Tse N; Cane P; Glaspy J
Gynecol Oncol; 1993 Nov; 51(2):175-81. PubMed ID: 8276290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
